Piramal Pharma Limited — Board Meeting, 28-07-2025: Outcome of Board Meeting

Piramal Pharma's Board has approved the consolidated financial results for the quarter ended June 30, 2025. The company reported revenue from operations of Rs 1,933.71 Cr, a slight decrease from Rs 1,951.14 Cr last year. The net loss after tax for the quarter was Rs 81.70 Cr, showing a minor improvement from Rs 88.64 Cr in the same quarter last year. A positive exceptional item of Rs 20.74 Cr from an insolvency settlement contributed to this. This update offers key insights for retail investors into the company's recent performance.